Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial
K Borowczyk, J Piechocka, R Głowacki, I Dhar, Ø Midtun, G S Tell, P M Ueland, O Nygård, H Jakubowski, K Borowczyk, J Piechocka, R Głowacki, I Dhar, Ø Midtun, G S Tell, P M Ueland, O Nygård, H Jakubowski
Abstract
Objectives: No individual homocysteine (Hcy) metabolite has been studied as a risk marker for coronary artery disease (CAD). Our objective was to examine Hcy-thiolactone, a chemically reactive metabolite generated by methionyl-tRNA synthetase and cleared by the kidney, as a risk predictor of incident acute myocardial infarction (AMI) in the Western Norway B-Vitamin Intervention Trial.
Design: Single centre, prospective double-blind clinical intervention study, randomized in a 2 × 2 factorial design.
Subjects and methods: Patients with suspected CAD (n = 2049, 69.8% men; 61.2-year-old) were randomized to groups receiving daily (i) folic acid (0.8 mg)/vitamin B12 (0.4 mg)/vitamin B6 (40 mg); (ii) folic acid/vitamin B12 ; (iii) vitamin B6 or (iv) placebo. Urinary Hcy-thiolactone was quantified at baseline, 12 and 38 months.
Results: Baseline urinary Hcy-thiolactone/creatinine was significantly associated with plasma tHcy, ApoA1, glomerular filtration rate, potassium and pyridoxal 5'-phosphate (positively) and with age, hypertension, smoking, urinary creatinine, plasma bilirubin and kynurenine (negatively). During median 4.7-years, 183 patients (8.9%) suffered an AMI. In Cox regression analysis, Hcy-thiolactone/creatinine was associated with AMI risk (hazard ratio = 1.58, 95% confidence interval = 1.10-2.26, P = 0.012 for trend; adjusted for age, gender, tHcy). This association was confined to patients with pyridoxic acid below median (adjusted HR = 2.72, 95% CI = 1.47-5.03, P = 0.0001; Pinteraction = 0.020). B-vitamin/folate treatments did not affect Hcy-thiolactone/creatinine and its AMI risk association.
Conclusions: Hcy-thiolactone/creatinine ratio is a novel AMI risk predictor in patients with suspected CAD, independent of traditional risk factors and tHcy, but modified by vitamin B6 catabolism. These findings lend a support to the hypothesis that Hcy-thiolactone is mechanistically involved in cardiovascular disease.
Trial registration: ClinicalTrials.gov NCT00354081.
Keywords: B-vitamins; acute myocardial infarction; atherosclerosis; homocysteine thiolactone; paraoxonase.
© 2018 The Authors Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
Figures
References
- Mudd SH, Finkelstein JD, Refsum H et al Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 2000; 20: 1704–6.
- Refsum H, Smith AD, Ueland PM et al Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004; 50: 3–32.
- Refsum H, Nurk E, Smith AD et al The Hordaland Homocysteine Study: a community‐based study of homocysteine, its determinants, and associations with disease. J Nutr 2006; 136: 1731S–40S.
- Clarke R, Halsey J, Lewington S et al Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause‐specific mortality: Meta‐analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010; 170: 1622–31.
- Zhang C, Wang ZY, Qin YY, Yu FF, Zhou YH. Association between B vitamins supplementation and risk of cardiovascular outcomes: a cumulative meta‐analysis of randomized controlled trials. PLoS ONE 2014; 9: e107060.
- Marti‐Carvajal AJ, Sola I, Lathyris D, Dayer M. Homocysteine‐lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2017; 8: CD006612.
- Jakubowski H. The molecular basis of homocysteine thiolactone‐mediated vascular disease. Clin Chem Lab Med 2007; 45: 1704–16.
- Undas A, Jakubowski H. Letter by Undas and Jakubowski regarding article, “Relationship between homocysteine and mortality in chronic kidney disease”. Circulation 2006; 114: e547; author reply e8.
- Jakubowski H. Quality control in tRNA charging. Wiley Interdiscip Rev RNA 2012; 3: 295–310.
- Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res 2000; 87: 45–51.
- Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999; 13: 2277–83.
- Jakubowski H. Homocysteine in Protein Structure/Function and Human Disease ‐ Chemical Biology of Homocysteine‐containing Proteins. Wien: Springer, 2013.
- Perla‐Kajan J, Utyro O, Rusek M, Malinowska A, Sitkiewicz E, Jakubowski H. N‐Homocysteinylation impairs collagen cross‐linking in cystathionine beta‐synthase‐deficient mice: a novel mechanism of connective tissue abnormalities. FASEB J 2016; 30: 3810–21.
- Chwatko G, Jakubowski H. Urinary excretion of homocysteine‐thiolactone in humans. Clin Chem 2005; 51: 408–15.
- Chwatko G, Jakubowski H. The determination of homocysteine‐thiolactone in human plasma. Anal Biochem 2005; 337: 271–7.
- Gurda D, Handschuh L, Kotkowiak W, Jakubowski H. Homocysteine thiolactone and N‐homocysteinylated protein induce pro‐atherogenic changes in gene expression in human vascular endothelial cells. Amino Acids 2015; 47: 1319–39.
- Jakubowski H, Perla‐Kajan J, Finnell RH et al Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N‐homocysteinylation in mice. FASEB J 2009; 23: 1721–7.
- Jakubowski H, Boers GH, Strauss KA. Mutations in cystathionine beta‐synthase or methylenetetrahydrofolate reductase gene increase N‐homocysteinylated protein levels in humans. FASEB J 2008; 22: 4071–6.
- Ebbing M, Bleie O, Ueland PM et al Mortality and cardiovascular events in patients treated with homocysteine‐lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008; 300: 795–804.
- Jakubowski H, Borowczyk K, Glowacki R, Nygård O. Urinary homocysteine thiolactone predicts acute myocardial infarction in a randomized controlled homocysteine‐lowering B‐vitamin trial. Circulation 2015; 132: A19250.
- Sulo E, Vollset SE, Nygard O et al Trends in 28‐day and 1‐year mortality rates in patients hospitalized for a first acute myocardial infarction in Norway during 2001‐2009: a “Cardiovascular disease in Norway” (CVDNOR) project. J Intern Med 2015; 277: 353–61.
- Glowacki R, Bald E, Jakubowski H. An on‐column derivatization method for the determination of homocysteine‐thiolactone and protein N‐linked homocysteine. Amino Acids 2011; 41: 187–94.
- Schartum‐Hansen H, Ueland PM, Pedersen ER et al Assessment of urinary betaine as a marker of diabetes mellitus in cardiovascular patients. PLoS ONE 2013; 8: e69454.
- Bleie O, Semb AG, Grundt H et al Homocysteine‐lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J Intern Med 2007; 262: 244–53.
- Pedersen ER, Svingen GF, Schartum‐Hansen H et al Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography. Eur Heart J 2013; 34: 2689–96.
- Eisenga MF, Kieneker LM, Soedamah‐Muthu SS et al Urinary potassium excretion, renal ammoniagenesis, and risk of graft failure and mortality in renal transplant recipients. Am J Clin Nutr 2016; 104: 1703–11.
- VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E‐value. Ann Intern Med 2017; 167: 268–74.
- Clarke R, Woodhouse P, Ulvik A et al Variability and determinants of total homocysteine concentrations in plasma in an elderly population. Clin Chem 1998; 44: 102–7.
- Chwatko G, Boers GH, Strauss KA, Shih DM, Jakubowski H. Mutations in methylenetetrahydrofolate reductase or cystathionine beta‐synthase gene, or a high‐methionine diet, increase homocysteine thiolactone levels in humans and mice. FASEB J 2007; 21: 1707–13.
- Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 2010; 26: 150–71.
- Zimmerli LU, Schiffer E, Zurbig P et al Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics 2008; 7: 290–8.
- Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D. Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 2006; 15: 631–6.
- Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537–43.
- Borowczyk K, Shih DM, Jakubowski H. Metabolism and neurotoxicity of homocysteine thiolactone in mice: evidence for a protective role of paraoxonase 1. J Alzheimers Dis 2012; 30: 225–31.
- Borowczyk K, Tisonczyk J, Jakubowski H. Metabolism and neurotoxicity of homocysteine thiolactone in mice: protective role of bleomycin hydrolase. Amino Acids 2012; 43: 1339–48.
- Mercie P, Garnier O, Lascoste L et al Homocysteine‐thiolactone induces caspase‐independent vascular endothelial cell death with apoptotic features. Apoptosis 2000; 5: 403–11.
- Perla‐Kajan J, Stanger O, Luczak M et al Immunohistochemical detection of N‐homocysteinylated proteins in humans and mice. Biomed Pharmacother 2008; 62: 473–9.
- Gu W, Lu J, Yang G et al Plasma homocysteine thiolactone associated with risk of macrovasculopathy in Chinese patients with type 2 diabetes mellitus. Adv Ther 2008; 25: 914–24.
- Yang X, Gao Y, Zhou J et al Plasma homocysteine thiolactone adducts associated with risk of coronary heart disease. Clin Chim Acta 2006; 364: 230–4.
- Undas A, Jankowski M, Twardowska M, Padjas A, Jakubowski H, Szczeklik A. Antibodies to N‐homocysteinylated albumin as a marker for early‐onset coronary artery disease in men. Thromb Haemost 2005; 93: 346–50.
- Undas A, Perla J, Lacinski M, Trzeciak W, Kazmierski R, Jakubowski H. Autoantibodies against N‐homocysteinylated proteins in humans: implications for atherosclerosis. Stroke 2004; 35: 1299–304.
- Jakubowski H. Homocysteine is a protein amino acid in humans. Implications for homocysteine‐linked disease. J Biol Chem 2002; 277: 30425–8.
- Undas A, Stepien E, Glowacki R, Tisonczyk J, Tracz W, Jakubowski H. Folic acid administration and antibodies against homocysteinylated proteins in subjects with hyperhomocysteinemia. Thromb Haemost 2006; 96: 342–7.
- Strauss KA, Morton DH, Puffenberger EG et al Prevention of brain disease from severe 5,10‐methylenetetrahydrofolate reductase deficiency. Mol Genet Metab 2007; 91: 165–75.
- Jakubowski H. Protective mechanisms against protein damage in hyperhomocysteinemia: Systemic and renal detoxification of homocysteine‐thiolactone. Biomed Genet Genom 2016; 1: 40–3.
- Marsillach J, Suzuki SM, Richter RJ et al Human valacyclovir hydrolase/biphenyl hydrolase‐like protein is a highly efficient homocysteine thiolactonase. PLoS ONE 2014; 9: e110054.
- Zimny J, Sikora M, Guranowski A, Jakubowski H. Protective mechanisms against homocysteine toxicity: the role of bleomycin hydrolase. J Biol Chem 2006; 281: 22485–92.
- Zimny J, Bretes E, Grygiel D, Guranowski A. Human mitochondrial homocysteine thiolactone hydrolase; overexpression and purification. Acta Biochim Pol 2011; 58(Suppl 4): 57.
- Perla‐Kajan J, Borowczyk K, Glowacki R, Nygard O, Jakubowski H. Paraoxonase 1 Q192R genotype and activity affect homocysteine thiolactone levels in humans. FASEB J 2018. 10.1096/fj.201800346R [Epub ahead of print]
- Hassan A, Dohi T, Miyauchi K et al Prognostic impact of homocysteine levels and homocysteine thiolactonase activity on long‐term clinical outcomes in patients undergoing percutaneous coronary intervention. J Cardiol 2017; 69: 830–5.
Source: PubMed